Kalaris Therapeutics files resale prospectus for 5M shares by selling stockholders; company gets no proceeds

Filed April 13, 2026 · ~1 min read

Key Changes

• high

  This is a secondary offering of 5,000,000 shares by selling stockholders; Kalaris will not receive any proceeds from the sales.

  The Offering verify on EDGAR →
• medium

  The shares consist of 4,200,000 outstanding shares and 800,000 shares underlying pre-funded warrants with a $0.0001 exercise price.

  The Offering verify on EDGAR →
• high

  Samsara BioCapital owns over 50% of shares, making Kalaris a 'controlled company' under Nasdaq rules, allowing governance exemptions.

  Prospectus Summary verify on EDGAR →